Preferred Label : daratumumab;

UMLS semantic type : T116 - Amino Acid, Peptide, or Protein; T129 - Immunologic Factor;

Is substance : O;

Details


Main resources

You can consult :


https://www.has-sante.fr/jcms/p_3334268/fr/darzalex-daratumumab-myelome-multiple
2022
France
evaluation of the transparency committee
multiple myeloma
daratumumab
Myeloma
Darzalex
Myeloma
daratumumab
multiple myeloma

---
https://www.has-sante.fr/jcms/p_3320599/fr/darzalex-daratumumab-amylose-systemique-a-chaines-legeres
2022
France
evaluation of the transparency committee
Darzalex
amyloid deposition, nos
chain
daratumumab
daratumumab
amyloidosis, nos
amylose

---
https://has-sante.fr/jcms/p_3292242/fr/decision-n-2021-0262/dc/sem-du-7-octobre-2021-du-college-de-la-haute-autorite-de-sante-constatant-l-impact-significatif-du-produit-darzalex-daratumumab-1800-mg-sur-les-depenses-de-l-assurance-maladie
2021
France
public health guidelines
Darzalex
Insurance
health
health expenditures
7-methylbenzanthracene
daratumumab
daratumumab
disease, nos
Diseases
expenditures
schools
insurance, health
Disease

---
https://has-sante.fr/jcms/p_3183488/fr/darzalex-daratumumab
2020
France
evaluation of the transparency committee
indicators
indicators and reagents
daratumumab
daratumumab
Darzalex
traction
indication of

---
https://has-sante.fr/jcms/p_3183497/fr/darzalex-daratumumab
2020
France
evaluation of the transparency committee
daratumumab
Darzalex
daratumumab

---
Nous contacter.
29/05/2025


[Home] [Top]

© Rouen University Hospital. Any partial or total use of this material must mention the source.